{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["21(1)"],"submitter":["Luo J"],"pubmed_abstract":["The APOLLO trial demonstrated that anlotinib plus penpulimab significantly prolonged progression-free survival (PFS) and overall survival compared to sorafenib in patients with unresectable hepatocellular carcinoma (HCC). However, its cost-effectiveness remains uncertain. This study aimed to evaluate the cost-effectiveness of this regimen from the perspective of the Chinese healthcare system. We constructed a partitioned survival model comprising three health states to evaluate the cost-effectiveness of anlotinib plus penpulimab versus sorafenib for unresectable HCC. Over a 10-y time horizon, we compared the total costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) between two groups. The robustness of the results was validated through one-way sens"],"journal":["Human vaccines & immunotherapeutics"],"pagination":["2582294"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12674322"],"repository":["biostudies-literature"],"pubmed_title":["Cost-effectiveness analysis of anlotinib plus penpulimab versus sorafenib in the treatment of unresectable hepatocellular carcinoma."],"pmcid":["PMC12674322"],"pubmed_authors":["Gui C","Du Q","Liu J","Li Z","Luo J"],"additional_accession":[]},"is_claimable":false,"name":"Cost-effectiveness analysis of anlotinib plus penpulimab versus sorafenib in the treatment of unresectable hepatocellular carcinoma.","description":"The APOLLO trial demonstrated that anlotinib plus penpulimab significantly prolonged progression-free survival (PFS) and overall survival compared to sorafenib in patients with unresectable hepatocellular carcinoma (HCC). However, its cost-effectiveness remains uncertain. This study aimed to evaluate the cost-effectiveness of this regimen from the perspective of the Chinese healthcare system. We constructed a partitioned survival model comprising three health states to evaluate the cost-effectiveness of anlotinib plus penpulimab versus sorafenib for unresectable HCC. Over a 10-y time horizon, we compared the total costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) between two groups. The robustness of the results was validated through one-way sens","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-07-16T07:26:22.717Z","creation":"2026-07-09T10:43:55.894Z"},"accession":"S-EPMC12674322","cross_references":{"pubmed":["41326976"],"doi":["10.1080/21645515.2025.2582294"]}}